Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
CCND1 595 ARSENIC TRIOXIDE CHEMBL1200978 antagonist TdgClinicalTrial, DrugBank 12480548, 16230390, 17005224, 16387740, 17370311
CCND1 595 URACIL CHEMBL566 NCI 10607743
CCND1 595 Ribociclib CHEMBL3545110 ClearityFoundationBiomarkers
CCND1 595 MYCOPHENOLIC ACID CHEMBL866 NCI 16123159
CCND1 595 ABEMACICLIB CHEMBL3301610 ClearityFoundationBiomarkers
CCND1 595 BRICICLIB CHEMBL1206245 inhibitor ChemblInteractions
CCND1 595 PALBOCICLIB CHEMBL189963 inhibitor ClearityFoundationBiomarkers, ChemblInteractions
CCND1 595 TAMOXIFEN CHEMBL83 NCI, CIViC 12469160, 12602925, 15138475
CCND1 595 ACETAMINOPHEN CHEMBL112 NCI 11896290
CCND1 595 CYTARABINE CHEMBL803 NCI 15936818
CCND1 595 Roniciclib CHEMBL3544942 ClearityFoundationBiomarkers
CCND1 595 GOSSYPOL CHEMBL51483 NCI 11510695
CCND1 595 NIFEDIPINE CHEMBL193 NCI 10051745
CCND1 595 VITAMIN E CHEMBL47 NCI 14871472
CCND1 595 METHOTREXATE CHEMBL34259 NCI 12972956
CCND1 595 TROGLITAZONE CHEMBL408 NCI 14764597

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
CCND1 rs9344 CA/CA + CA/CG lapatinib efficacy no The genotype association was not significant in univariate analysis but when looking at A carriers those on capecitabine plus lapatinib did significantly better than those on capecitabine alone whereas for the G homozygotes the outcomes were similar for both drug combinations. Genotypes CA/CA + CA/CG are associated with increased response to lapatinib in women with Breast Neoplasms as compared to genotype CG/CG. 21989330 982010231
CCND1 rs9344 A cetuximab efficacy no Allele A is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele G. 18349392 827843529
CCND1 rs9344 A cetuximab efficacy no Meta-analysis with 5 studies. This variant was listed as rs17852153 in the original article. The authors did not provide the exact number of patients but stated that "the median number of patients per analysis was 110 (range 50 - 740)". Most definitions of response were variations of the RECIST criteria. Allele A is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele G. 27897268 1449165334